|
Latest Reports
|
| Date |
Description |
Country |
Analyst |
Download |
|
|
| 15-Nov-2019 |
Glenmark Pharma - Core earnings concern remains; Remain Neutral with TP Rs 340 |
India |
Surya Patra |
 |
| 14-Aug-2019 |
Glenmark Pharma (GNP IN) - Operational challenges persist; NEUTRAL with TP Rs 430 |
India |
Anjali Verma |
|
| 31-May-2019 |
Glenmark Pharma (GNP IN) - Weak US outlook raise earnings growth concerns; NEUTRAL with TP Rs 570: |
India |
Surya Patra |
|
| 15-Feb-2019 |
Glenmark Pharma (GNP IN) - Operating performance drags earnings; NEUTRAL with TP of Rs 620: |
India |
Surya Patra |
|
| 14-Nov-2018 |
Glenmark Pharma (GNP IN) - Guides for sequential operating progress; NEUTRAL with TP of Rs 610: |
India |
Surya Patra |
|
| 14-Aug-2018 |
Glenmark Pharma (GNP IN) - Q1-miss; Visible progress in R&D assets could surprise; NEUTRAL with TP of Rs 550 |
India |
Surya Patra |
|
| 30-May-2018 |
Glenmark Pharma - Growth challenges in US create margin concerns; NEUTRAL with TP of Rs 570 |
India |
Surya Patra |
|
| 09-Feb-2018 |
Glenmark Pharma - Bleak US outlook is worrisome; Downgrade to NEUTRAL with TP of Rs 640 |
India |
Surya Patra |
|
| 06-Nov-2017 |
Glenmark Pharma (GNP IN) - Attractive valuations but US challenges persist; BUY with TP of Rs 750: |
India |
Surya Patra |
|
| 30-Jul-2017 |
Glenmark Pharma (GNP IN) - Strong Q1, but no debt reduction remains a concern; BUY with TP of Rs 830 |
India |
Surya Patra |
|
| 12-May-2017 |
Glenmark Pharma (GNP IN) - Price competition in the US and static net debt concerns; BUY with TP of Rs 910: |
India |
Surya Patra |
|
| 03-Feb-2017 |
Glenmark Pharma (GNP IN) - Front loading of gZetia delivers huge positive surprise: Retain BUY with TP of Rs 1100 |
India |
Surya Patra |
|
| 13-Dec-2016 |
Glenmark Pharma (GNP IN) - gZetia ensures healthy growth phase; Retain BUY with TP of Rs 1,100 |
India |
Surya Patra |
|
| 28-Oct-2016 |
Glenmark Pharma (GNP IN) - Set to enter a healthy growth phase; Maintain BUY with a TP of Rs 1100: |
India |
Surya Patra |
|
| 16-Aug-2016 |
Glenmark - US business set for sequential progress; Re-iterate BUY with TP of Rs 1000 |
India |
Surya Patra |
|
| 13-May-2016 |
Glenmark Pharma - Foresees broad-based growth; Maintain BUY with a raised TP of Rs 1050 |
India |
Surya Patra |
|
| 29-Jan-2016 |
Glenmark Pharma (GNP IN) - Disappointing results, but priced in; Upgrade to BUY with TP of Rs 930: |
India |
Surya Patra |
|
| 30-Oct-2015 |
Glenmark Pharma (GNP IN) - Bets big on US sales progress in H2 |
India |
Surya Patra |
|
| 31-Jul-2015 |
Glenmark Pharma (GNP IN) - No marked improvement in US sales |
India |
Surya Patra |
|
| 02-Jun-2015 |
Glenmark Pharma (GNP IN) - Guides for better US growth visibility |
India |
Surya Patra |
|
| 13-Feb-2015 |
Glenmark Pharma - US generics to drive value growth |
India |
Surya Patra |
|
| 25-Jul-2014 |
Glenmark Pharma - Foresees al-round progress across geographie |
India |
Surya Patra |
|
| 09-May-2014 |
Glenmark Pharma - Strong earnings but faced a setback in discovery R&D |
India |
Surya Patra |
|
| 29-Apr-2014 |
Glenmark Pharma Management Meet Note - Upgrade to conviction BUY with upward revised TP of Rs 744 |
India |
Surya Patra |
|
| 27-Jan-2014 |
Glenmark Pharma - Right value prescription |
India |
Surya Patra |
|
|
|